[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

613.O1.6 Acute Myeloid Leukemia - Biology and Pathophysiology: Genetics and Genomics of AML

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 6, 2010: 7:00 AM-8:30 AM
308 (Orange County Convention Center)
Timothy A. Graubert, MD, Washington University and Susanne Schnittger, MLL Munich Leukemia Laboratory
7:00 AM
Targeted Next-Generation Sequencing (NGS) Enables a Broad Screening of 95 Molecular Mutations In a One-Step Approach and Detects Recurrent Mutations In AML with a Normal Karyotype In MYH11 and NOTCH1

Alexander Kohlmann, PhD1, Vera Grossmann, MA1*, Hans-Ulrich Klein, PhD2*, Susanne Schnittger, PhD1, Martin Dugas, MD2*, Wolfgang Kern, MD1, Claudia Haferlach, MD1 and Torsten Haferlach1

1MLL Munich Leukemia Laboratory, Munich, Germany
2Institute of Medical Informatics, University of Muenster, Muenster, Germany

7:15 AM
TET2 Mutations in Secondary Acute Myeloid Leukemias : A French Retrospective Study

Olivier Kosmider1*, Véronique De Mas2*, Eric Delabesse3*, Pascale Cornillet-lefevre4*, Odile Blanchet5*, Christian Récher6*, Sophie Raynaud7*, Catherine Lacombe8, Olivier Bernard9*, Norbert Ifrah10, Francois Dreyfus11* and Michaëla Fontenay on behalf of the GOELAMS12*

1Laboratory of Hematology., APHP Cochin Hospital, Inserm U1016 CNRS UMR 8104, Cochin Institute, University Paris Descartes, Faculty of Medicine, Paris, France
2Laboratory of Hematology, CHU Purpan, Toulouse
3Hôpital Purpan Université de Toulouse, Toulouse, France
4Laboratory of Hematology, CHU de Reims, Reims
5CHU Angers, Université Angers, Angers, France
6Service d'Hématologie clinique, CHU Purpan, Toulouse, France
7Laboratory of Hematology, CHU L'Archet, University of Nice, Nice, France
8Laboratory of Hematology, APHP, Cochin Hospital, Inserm U1016 CNRS UMR 8104, Cochin Institute, University Paris Descartes, Faculty of Medicine, Paris, France
9Inserm U985, Institut Gustave Roussy, Villejuif, Villejuif, France
10Service des Maladies du Sang, CHU Angers, France
11Inserm U1016 CNRS UMR 8104, University Paris 5, Faculty of Medicine Réné Descartes, UM 3, Cochin Institute, Internal Medicine Department, Paris
12Inserm U1016 CNRS UMR 8104, University Paris 5, Faculty of Medicine Réné Descartes, UM 3, Cochin Hospital, APHP, Cochin Institute, Hematology Department, Paris, France

7:30 AM
Identification of Potential Therapeutic Targets Using Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML)

Sophia Adamia, Ph.D1, Hervé Avet-Loiseau, MD, PhD2, Laurence Lodé3*, Michal Bar-Natan4*, Sigitas Verselis, PhD5*, Edward Fox, PhD6*, Ilene Galinsky, ANP7, Philippe Moreau8*, Richard Stone, MD9* and James D. Griffin, MD10

1Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
2Hematology, CHU-Nantes, Nantes, France
3Hopital de Nantes, Nantes
4Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
5Molecular Diagnostics Laboratory, Dana Farber Cancer Institute, Boston, MA
6Microarray Core, Dana Farber Cancer Institute, Boston, MA
7Adult Leukemia Program, Dana Farber Cancer Inst., Boston, MA
8Hematology Department, CHU de Nantes, Nantes, France
9Dana Farber Cancer Institute, Boston, MA
10Department of Medical Oncology, Dana-Farber Cancer Institiute, Harvard Medical School, Boston, MA

7:45 AM
Single-Cell Phylogenetic analysis provides Novel Insight Into Resistance Mechanisms In AML

Liran I Shlush1*, Noa Chapal2*, Rivka Adar2*, Shai Izraeli3, Jacob M. Rowe, MD4, Karl Skorecki5*, Ehud Shapiro2* and Tsila Zuckerman, MD6*

1Internal Medicine B, Rambam HealthCare Campus, Haifa, Israel
2Department of Computer Science and Applied Mathematics, and Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel
3Sheba Medical Center, Pediatric Hematology Oncology, Tel Hashomer, Ramat Gan and Tel Aviv University, Tel Aviv, Israel
4Hematology and Bone Marrow Transplantation, Rambam Medical Center, Technion, Haifa, Israel
5Medicine, Technion Institute of Technology, Haifa, Israel
6Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

8:00 AM
Transcriptional Activity of MEF/ELF4 on the HDM2 Promoter Is Enhanced by the Mutation of the NPM1 Gene

Koji Ando, MD1*, Emi Matsuo, MD, PhD1*, Kensuke Horio, MD1*, Shinya Tominaga, MD1*, Daisuke Imanishi, MD, PhD1*, Yoshitaka Imaizumi, MD, PhD1*, Hideki Tsushima, MD, PhD1*, Masako Iwanaga, MD, PhD, MPH1, Hitoshi Kiyoi, MD, PhD2, Tomoki Naoe, MD, PhD3 and Yasushi Miyazaki, MD, PhD1

1Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
2Dept. of Infectious Disease, Nagoya Univ. Graduate School of Med., Nagoya, Japan
3Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

8:15 AM
Phosphatome and Kinome RNAi Screen In Leukemia

Raoul Tibes, MD, PhD1, James M Bogenberger, PhD2*, Donald Chow3*, Irma Gonzales3*, David Azorsa, PhD3* and Holly Yin3*

1Cancer Center, Mayo Clinic, Scottsdale, AZ
2Mayo Clinic, Scottsdale, AZ
3TGen, Scottsdale, AZ

*signifies non-member of ASH